Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis

Malaria Journal

Research

Komal Raj Rijal¹  Saber Dini²  Parinaz Mehdipour²  Megha Rajasekhar²  Sophie Zaloumis²  Julie A. Simpson³  Ric N. Price⁴  Cindy S. Chu⁵  Philippe J. Guerin⁶  Dhelio B. Pereira⁷  Kavitha Saravu⁸  Toby Leslie⁹  Liwang Cui^1,10  Harin Karunajeewa^1,11  Ishag Adam^1,12  Inge Sutanto^1,13  Kartini Lidia^1,14  Larissa W. Brasil^1,15  José Luiz F. Vieira^1,16  André Daher^1,17  Marcus V. G. Lacerda^1,18  Benedikt Ley^1,19  Kamala Thriemer^1,19  Robert J. Commons^2,20  Lina M. Zuluaga-Idarraga^2,21  Tesfay Abreha^2,22  Simone Ladeia-Andrade^2,23  Nicholas J. White^2,24  Walter R. J. Taylor^2,24  Ghulam Rahim Awab^2,25  Rhea J. Longley^2,26  Pham Vinh Thanh^2,27  J. Kevin Baird^2,28  Lilia Gonzalez‑Ceron^2,29  Margarete do Socorro M Gomes^3,30  Jimee Hwang^3,31  Alejandro Llanos-Cuentas^3,32  Wuelton Marcelo Monteiro^3,33 

[1] Central Department of Microbiology, Tribhuvan University, Kirtipur, Kathmandu, Nepal;Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand;Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia;Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia;WorldWide Antimalarial Resistance Network (WWARN), Asia-Pacific Regional Centre, Darwin, NT, Australia;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK;Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia;WorldWide Antimalarial Resistance Network (WWARN), Asia-Pacific Regional Centre, Darwin, NT, Australia;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK;Shoklo Malaria Research Unit, Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK;WorldWide Antimalarial Resistance Network (WWARN), Oxford, UK;Infectious Diseases Data Observatory (IDDO), Oxford, UK;Centro de Pesquisa Em Medicina Tropical de Rondonia (CEPEM), Porto Velho, Brazil;Fundação Universidade Federal de Rondonia (UNIR), Porto Velho, Brazil;Department of Infectious Diseases, Kasturba Medical College Manipal, Manipal Academy of Higher Education, Madhava Nagar, Manipal, Karnataka, India;Manipal Centre for Infectious Diseases, Prasanna School of Public Health, Manipal Academy of Higher Education, Madhava Nagar, Manipal, Karnataka, India;Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK;HealthNet-TPO, Kabul, Afghanistan;Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA;Department of Medicine-Western Health, Melbourne Medical School, The University of Melbourne, St. Albans, VIC, Australia;Department of Obstetrics and Gynecology, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah, Saudi Arabia;Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia;Department of Pharmacology and Therapy, Faculty of Medicine and Veterinary Medicine, Universitas Nusa Cendana, Kupang, Indonesia;Diretoria de Ensino E Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, AM, Brazil;Programa de Pós‑Graduação em Medicina Tropical, Universidade Do Estado Do Amazonas, Manaus, AM, Brazil;Federal University of Pará, Universidade Federal Do Pará - UFPA), Belém, Pará, Brazil;Fiocruz Clinical Research Platform, Vice-Presidency of Research and Biological Collections, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil;Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil;Instituto Leônidas & Maria Deane, Fiocruz, Manaus, Brazil;University of Texas Medical Branch, Galveston, USA;Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia;Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia;WorldWide Antimalarial Resistance Network (WWARN), Asia-Pacific Regional Centre, Darwin, NT, Australia;General and Subspecialty Medicine, Grampians Health – Ballarat, Ballarat, Australia;Grupo Malaria, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia;Facultad Nacional de Salud Publica, Universidad de Antioquia, Medellín, Colombia;ICAP, Columbia University Mailman School of Public Health, Addis Ababa, Ethiopia;Laboratory of Parasitic Diseases, Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, Brazil;Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, Nova University of Lisbon, Lisbon, Portugal;Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK;Mahidol Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand;Nangarhar Medical Faculty, Nangarhar University, Jalalabad, Afghanistan;Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand;Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia;Department of Medical Biology, University of Melbourne, Melbourne, Australia;National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam;Oxford University Clinical Research Unit Indonesia, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia;Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK;Regional Centre for Public Health Research, National Institute for Public Health, Tapachula, Chiapas, Mexico;Superintendência de Vigilância Em Saúde Do Estado Do Amapá - SVS/AP, Macapá, Amapá, Brazil;Federal University of aMAPA, Universidade Federal Do Amapá - UNIFAP), Macapá, Amapá, Brazil;U.S. President’s Malaria Initiative, Malaria Branch, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA;Global Health Group, University of California San Francisco, San Francisco, USA;Unit of Leishmaniasis and Malaria, Instituto de Medicina Tropical “Alexander Von Humboldt”, Universidad Peruana Cayetano Heredia, Lima, Peru;Universidade Do Estado Do Amazonas, Manaus, Brazil;

关键词: Malaria;    Plasmodium vivax;    Adherence;    Primaquine;    Rate of recurrence;    Supervision;   

DOI  :  10.1186/s12936-023-04725-w

 received in 2023-08-24, accepted in 2023-09-25,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundImperfect adherence is a major barrier to effective primaquine radical cure of Plasmodium vivax. This study investigated the effect of reduced adherence on the risk of P. vivax recurrence.MethodsEfficacy studies of patients with uncomplicated P. vivax malaria, including a treatment arm with daily primaquine, published between January 1999 and March 2020 were identified. Individual patient data from eligible studies were pooled using standardized methodology. Adherence to primaquine was inferred from i) the percentage of supervised doses and ii) the total mg/kg dose received compared to the target total mg/kg dose per protocol. The effect of adherence to primaquine on the incidence of P. vivax recurrence between days 7 and 90 was investigated by Cox regression analysis.ResultsOf 82 eligible studies, 32 were available including 6917 patients from 18 countries. For adherence assessed by percentage of supervised primaquine, 2790 patients (40.3%) had poor adherence (≤ 50%) and 4127 (59.7%) had complete adherence. The risk of recurrence by day 90 was 14.0% [95% confidence interval: 12.1–16.1] in patients with poor adherence compared to 5.8% [5.0–6.7] following full adherence; p = 0.014. After controlling for age, sex, baseline parasitaemia, and total primaquine dose per protocol, the rate of the first recurrence was higher following poor adherence compared to patients with full adherence (adjusted hazard ratio (AHR) = 2.3 [1.8–2.9]). When adherence was quantified by total mg/kg dose received among 3706 patients, 347 (9.4%) had poor adherence, 88 (2.4%) had moderate adherence, and 3271 (88.2%) had complete adherence to treatment. The risks of recurrence by day 90 were 8.2% [4.3–15.2] in patients with poor adherence and 4.9% [4.1–5.8] in patients with full adherence; p < 0.001.ConclusionReduced adherence, including less supervision, increases the risk of vivax recurrence.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 1

Fig. 2

Fig. 1

12951_2015_155_Article_IEq37.gif

13690_2023_1196_Figa_HTML.png

12944_2023_1927_Article_IEq25.gif

12951_2017_270_Article_IEq10.gif